SCHEMBL4008741

SCHEMBL4008741

Nc1n[nH]cc1CCc1ccco1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.38
BACE1 P56817 1/20 0.36
ALDH1A1 P00352 5/20 0.35
CYP3A4 P08684 1/20 0.35
ALOX15 P16050 1/20 0.35
USP2 O75604 1/20 0.35
HPGD P15428 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
KDM4E B2RXH2 2/20 0.35
HSD17B10 Q99714 1/20 0.35
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
MGMT P16455 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9833192 0.77 ALDH1A1 (0.37) ALDH1A1CYP3A4ALOX15USP2HPGD
SCHEMBL8146532 0.72 ALDH1A1 (0.54) GAAALDH1A1CYP3A4ALOX15USP2
SCHEMBL3940879 0.71 POLB (0.42) GAABACE1ALDH1A1CYP3A4ALOX15
SCHEMBL63642 0.68 PDPK1 (0.38) GAAALDH1A1CYP3A4ALOX15USP2
SCHEMBL11233568 0.67
SCHEMBL7497418 0.67
SCHEMBL7364092 0.67 PDPK1 (0.47) GAAALDH1A1ALOX15USP2HPGD
SCHEMBL3243024 0.67 GAA (0.44) GAABACE1ALDH1A1CYP3A4ALOX15
SCHEMBL28913489 0.66 CASP1 (0.43) GAAALDH1A1CYP3A4ALOX15USP2
SCHEMBL9376259 0.65 GFER (0.56) GAAALDH1A1CYP3A4ALOX15USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101501030-A Pyrimidine derivatives useful in the treatment of cancer ASTRAZENECA AB (SE) 2009-08-05 CN disclosed
EP-2044063-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Astra Zeneca AB (SE) 2009-04-08 EP disclosed
WO-2008001070-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-01-03 WO disclosed
US-20080004302-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004302-A1 Novel Compounds CYP11B2, CYP11B1, CYP46A1 GAA 159/4885BACE1 718/4885ALDH1A1 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.